DASH After TBI Study: Decreasing Adrenergic or Sympathetic Hyperactivity After Traumatic Brain Injury

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-08-31

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators intend to determine the effect of adrenergic blockade on 1) short-term physiology, behavior, and cognition and 2) long-term neuropsychological outcomes after severe Traumatic Brain Injury (TBI).

The primary hypothesis is that adrenergic blockade after severe TBI will be associated with increased ventilator-free days.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Early Propranolol After Traumatic Brain Injury: Phase II

NCT01202110

Traumatic Brain Injury

TERMINATED PHASE2

Using Propranolol in Traumatic Brain Injury to Reduce Sympathetic Storm Phenomenon

NCT03401515

Traumatic Brain Injury

COMPLETED PHASE4

Controlling Hyperadrenergic Activity in Neurologic Injury

NCT01343329

Traumatic Brain Injury Dysautonomia

WITHDRAWN PHASE1/PHASE2

Beta Blockade in in Traumatic Brain Injury

NCT02957331

Brain Injuries, Traumatic

COMPLETED PHASE4

Role of Non-Selective Beta-Adrenergic Blocker in Severe TBI

NCT06870370

Traumatic Brain Injury (TBI) Patients Intracranial Pressure Intensive Care Unit +1 more

NOT_YET_RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Severe traumatic brain injury (TBI) is associated with sympathetic hyperactivity resulting in catecholamine excess, abnormal heart rate variability, agitation and sympathetic storms, deep white matter changes, and poor neuropsychological outcomes. Notably, persistent sympathetic hyperactivity after TBI results in higher days of mechanical ventilation and longer intensive care unit (ICU) length of stay (LOS). While there are data describing limited portions of this response, the full spectrum of sympathetic hyperactivity after severe TBI has not been systemically described or methodically intervened upon.

We will perform a double-blinded, randomized, placebo-controlled pilot trial in a 100 patient cohort in which one group will receive centrally acting sympatholytic drugs, propranolol and clonidine, and the other group, placebo, within 48 hours of severe TBI. The length of therapy will be 7 days.

The primary question studied is whether ventilator-free days will be increased after therapy.

Secondary endpoints include plasma and urine catecholamine levels, heart rate and blood pressure variability, responses to autonomic cold pressor testing, assessments of coma, sedation, and agitation, sedative requirements, analgesic use, antipsychotic medication use, coma-free days, ventilator-free days, Intensive Care Unit (ICU) length of stay, and survival. Also, neuropsychological outcomes will be measured at ICU discharge, 3 months, and 12 months.

Interim Analysis: At approximately 50% targeted accrual, n=46 randomized subjects, an interim analysis will be performed with A Priori (planned) futility and efficacy rules, which are DSMB and IRB approved.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Brain Injuries Craniocerebral Trauma Trauma, Nervous System Traumatic Brain Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Adrenergic Blockade

Propranolol and Clonidine

Group Type EXPERIMENTAL

IV Propranolol and Per Tube Clonidine

Intervention Type DRUG

1 mg IV q6h Propranolol and 0.1 mg Per Tube Clonidine, both for 7 days

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo IV q6h and Per Tube q12, both for 7 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IV Propranolol and Per Tube Clonidine

1 mg IV q6h Propranolol and 0.1 mg Per Tube Clonidine, both for 7 days

Intervention Type DRUG

Placebo

Placebo IV q6h and Per Tube q12, both for 7 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age: 16 years to 64 years
* Glasgow Coma Scale score less than or equal to 8 (Severe TBI) with injury on CT
* Screen within 24 hours of injury

Exclusion Criteria

* Pre-existing heart disease (i.e. coronary heart disease)
* Pre-existing cardiac dysrhythmia
* Allergy to study drugs
* Penetrating brain injury
* Pre-existing brain dysfunction (i.e. prior severe TBI, debilitating stroke)
* Impending brain herniation (i.e. loss of bilateral corneal reflexes)
* Craniectomy or craniotomy
* Spinal cord injury
* Myocardial injury
* Severe liver disease
* Current use of beta-blockers and/or alpha-2-agonist
* Withdrawal of care expected in 24 hours
* Prisoners
* Pregnant women
* Unable to follow-up through final visit

Minimum Eligible Age

16 Years

Maximum Eligible Age

64 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No